By Iain Gilbert
Date: Tuesday 26 Mar 2019
LONDON (ShareCast) - (Sharecast News) - Internet-of-things investor Tern has seen one of its portfolio companies receive an initial order valued at more than £150,000 from an unnamed major pharmaceutical company.
FundamentalVR, a virtual reality training and data analysis technology platform, will create a VR simulation for the mystery global pharma outfit.
Tern stated the project was just the first in a planned series of VR experiences that FundamentalVR's client was commissioning to inform, educate and measure awareness and compliant, safe use of their products and was expected to become a template for future product launches.
Al Sisto, the AIM-listed group's chief executive, said: "This is a new approach to pharma and medical device product introductions, which we believe will accelerate the adoption of new medical products in building out the use procedures in a repeatable practice scenario were the individual's performance can be measured against a standard and his/her peers.
"FundamentalVR and its customers share the belief that the comparative data insights and measurements collected and available through the FundamentalVR platform will have a profoundly positive impact on medical outcomes and products around the world."
As of 1230 GMT, Tern shares had climbed 4% to 10.66p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 2.28p |
Change Today | 0.080p |
% Change | 3.64 % |
52 Week High | 8.50 |
52 Week Low | 1.70 |
Volume | 996,844 |
Shares Issued | 409.68m |
Market Cap | £9.34m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
08:37 | 10,000 @ 2.19p |
08:32 | 298,656 @ 2.14p |
08:31 | 44,543 @ 2.25p |
08:30 | 43,160 @ 2.16p |
08:29 | 12,500 @ 2.15p |
You are here: research